Modeling glioblastoma complexity with organoids for personalized treatments

Raue, Kristen D.; Duffy, Joseph T.; Babak, Maria V.; Balyasnikova, Irina V.

doi:10.1016/j.molmed.2023.01.002

Cited by 15 publications

(7 citation statements)

References 128 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is presently no definitive therapy for the lethal and recurrent brain tumour known as glioblastoma (GBM). 83 The potential of SAzymes in catalytic therapy for specific targeting of drug-resistant GBM through the lysosomal-mediated autophagic cell killing pathway was studied recently by Pir Muhammad et al 84 An ultrasmall carbon dots-supported iron SAzymes (Fe-CDs) that mimics six naturally occurring enzymes, including OXD, CAT, SOD, POD, glutathione peroxidase (GPx), and Thioredoxin peroxidase (TPx), has been created by their research team. Importantly, Fe-CDs function as a drug-free nanomedicine that modifies the tumor microenvironment through a variety of enzyme mimicking capabilities, regulating ROS and lysosome-mediated autophagy (Fig.…”

Section: Classification Of Sazymesmentioning

confidence: 99%

Single-atom nanozymes: classification, regulation strategy, and safety concerns

Han,

Gu,

Yang

et al. 2023

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

Section: Classification Of Sazymesmentioning

confidence: 99%

Single-atom nanozymes: classification, regulation strategy, and safety concerns

Han,

Gu,

Yang

et al. 2023

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

“…However, most patients with malignant glioma eventually die of disease progression caused by tumor recurrence due to resistance to TMZ. [4][5][6][7] Therefore, it is essential to develop strategies to overcome resistance to TMZ, which could signi cantly enhance the survival rates of glioma patients.…”

Section: Introductionmentioning

confidence: 99%

IL-18, a therapeutic target for immunotherapy boosting, promotes temozolomide chemoresistance via the PI3K/AKT pathway in glioma

Ji,

Lan,

Xing

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Temozolomide (TMZ) resistance is still the urgent topic in treatments of glioma. Recent studies show inflammation is involved in tumor chemoresistance.Interleukin-18, a proinflammatory cytokine, is highly expressed in glioma and related with worse prognosis. However, its effects on glioma remain unclear. Methods and Results: In this research, we detected that interleukin-18 enhanced growth and inhibited apoptosis in cultured glioma cells via CCK8 and EdU assay. Further, in vivo studies revealed that interleukin-18 promoted glioma growth in mice bearing tumors. Mechanical exploration indicated that interleukin-18 stimulation could activate the PI3K/AKT pathway, and the PI3K inhibition could reduce the interleukin-18-induced proliferation of glioma cells. We found that interleukin-18 upregulated CD274 expression in glioma cells.Furthermore, we established a tumor xenograft model and explored the therapeutic efficacy of anti-interleukin-18 monoclonal antibodies. Targeting interleukin-18 prolonged survival and attenuated CD274 expression in the mice-bearing tumor. Combined application of anti-PD-1 and anti-interleukin-18 monoclonal antibodies showed better efficacy in suppressing tumor growth than either treatment alone in mice bearing tumors. Conclusion: Interleukin-18 promotes temozolomide chemoresistance in glioma via PI3K/Akt activation and establishes an immunosuppressive milieu by modulating CD274. This study highlights the therapeutic value of interleukin-18 in glioma.

show abstract

“…For low‐grade gliomas, cure criteria can be achieved after total surgical resection, with a median survival of up to 50 years. In contrast, high‐grade gliomas are prone to recurrence, have a poor prognosis, and a short survival time even after surgical treatment 15 …”

Section: Introductionmentioning

confidence: 99%

“…In contrast, high‐grade gliomas are prone to recurrence, have a poor prognosis, and a short survival time even after surgical treatment. 15 …”

Section: Introductionmentioning

confidence: 99%

“…In contrast, high-grade gliomas are prone to recurrence, have a poor prognosis, and a short survival time even after surgical treatment. 15 Chemotherapy resistance is a common challenge in tumor therapy because tumor cells acquire resistance to chemotherapeutic drugs and are unable to effectively kill tumor cells. 16,17 This phenomenon is usually caused by biochemical mechanisms within the tumor cells, such as drug efflux, drug catabolism, DNA repair.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Nanoparticles for efficient drug delivery and drug resistance in glioma: New perspectives

Liu,

Yang,

et al. 2024

CNS Neurosci Ther

View full text Add to dashboard Cite

Gliomas are the most common primary tumors of the central nervous system, with glioblastoma multiforme (GBM) having the highest incidence, and their therapeutic efficacy depends primarily on the extent of surgical resection and the efficacy of postoperative chemotherapy. The role of the intracranial blood–brain barrier and the occurrence of the drug‐resistant gene O6‐methylguanine‐DNA methyltransferase have greatly limited the efficacy of chemotherapeutic agents in patients with GBM and made it difficult to achieve the expected clinical response. In recent years, the rapid development of nanotechnology has brought new hope for the treatment of tumors. Nanoparticles (NPs) have shown great potential in tumor therapy due to their unique properties such as light, heat, electromagnetic effects, and passive targeting. Furthermore, NPs can effectively load chemotherapeutic drugs, significantly reduce the side effects of chemotherapeutic drugs, and improve chemotherapeutic efficacy, showing great potential in the chemotherapy of glioma. In this article, we reviewed the mechanisms of glioma drug resistance, the physicochemical properties of NPs, and recent advances in NPs in glioma chemotherapy resistance. We aimed to provide new perspectives on the clinical treatment of glioma.

show abstract

Modeling glioblastoma complexity with organoids for personalized treatments

Cited by 15 publications

References 128 publications

Single-atom nanozymes: classification, regulation strategy, and safety concerns

Single-atom nanozymes: classification, regulation strategy, and safety concerns

IL-18, a therapeutic target for immunotherapy boosting, promotes temozolomide chemoresistance via the PI3K/AKT pathway in glioma

Nanoparticles for efficient drug delivery and drug resistance in glioma: New perspectives

Contact Info

Product

Resources

About